TY - GEN
T1 - Feasibility and Toxicity of Interval-Compressed Chemotherapy in Asian Children and Young Adults with Sarcoma
T2 - Journal of Personalized Medicine
AU - Huang, Jia-Hui
AU - Chen, Shu-Huey
AU - Liao, Yu-Mei
AU - Kao, Yu-Chien
AU - Ho, Wan-Ling
AU - Chang, Hsi
AU - Tsai, Min-Lan
AU - Lee, Hsin-Lun
AU - Kuo, Chia-Chun
AU - Tseng, Sung-Hui
AU - Chang, Chia-Yau
AU - Hsieh, Kevin L.
AU - Lu, Long-Sheng
AU - Chen, Yin-Ju
AU - Chiou, Jeng-Fong
AU - Hsieh, Tsung-Han
AU - Liu, Yun-Ru
AU - Hsu, Wayne
AU - Li, Wei-Tang
AU - Wu, Yu-Chung
AU - Wu, Wei-Ciao
AU - Wang, Jinn-Li
AU - Tsai, Jia-Jia
AU - Terashima, Keita
AU - Kiyotani, Chikako
AU - Wong, Tai-Tong
AU - Miser, James S.
AU - Liu, Yen-Lin
PY - 2023
Y1 - 2023
N2 - Twelve Asian patients with sarcoma received interval-compressed (ic-) chemotherapy scheduled every 14 days with a regimen of vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclophosphamide (1200–2200 mg/m2) (VDC) alternating with a regimen of ifosfamide (9000 mg/m2) and etoposide (500 mg/m2) (IE), with filgrastim (5–10 mcg/kg/day) between cycles. Carboplatin (800 mg/m2) was added for CIC-rearranged sarcoma. The patients were treated with 129 cycles of ic-VDC/IE with a median interval of 19 days (interquartile range [IQR], 15–24 days. Median nadirs (IQR) were neutrophil count, 134 (30–396) × 106/L at day 11 (10–12), recovery by day 15 (14–17) and platelet count, 35 (23–83) × 109/L at day 11 (10–13), recovery by day 17 (14–21). Fever and bacteremia were observed in 36% and 8% of cycles, respectively. The diagnoses were Ewing sarcoma (6), rhabdomyosarcoma (3), myoepithelial carcinoma (1), malignant peripheral nerve sheath tumor (1), and CIC-DUX4 Sarcoma (1). Seven of the nine patients with measurable tumors responded (one CR and six PR). Interval-compressed chemotherapy is feasible in the treatment of Asian children and young adults with sarcomas.
AB - Twelve Asian patients with sarcoma received interval-compressed (ic-) chemotherapy scheduled every 14 days with a regimen of vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclophosphamide (1200–2200 mg/m2) (VDC) alternating with a regimen of ifosfamide (9000 mg/m2) and etoposide (500 mg/m2) (IE), with filgrastim (5–10 mcg/kg/day) between cycles. Carboplatin (800 mg/m2) was added for CIC-rearranged sarcoma. The patients were treated with 129 cycles of ic-VDC/IE with a median interval of 19 days (interquartile range [IQR], 15–24 days. Median nadirs (IQR) were neutrophil count, 134 (30–396) × 106/L at day 11 (10–12), recovery by day 15 (14–17) and platelet count, 35 (23–83) × 109/L at day 11 (10–13), recovery by day 17 (14–21). Fever and bacteremia were observed in 36% and 8% of cycles, respectively. The diagnoses were Ewing sarcoma (6), rhabdomyosarcoma (3), myoepithelial carcinoma (1), malignant peripheral nerve sheath tumor (1), and CIC-DUX4 Sarcoma (1). Seven of the nine patients with measurable tumors responded (one CR and six PR). Interval-compressed chemotherapy is feasible in the treatment of Asian children and young adults with sarcomas.
KW - round cell sarcoma
KW - interval-compressed chemotherapy
KW - children
KW - adolescent and young adult
KW - VDC/IE
KW - granulocyte colony-stimulating factor
U2 - 10.3390/jpm13040668
DO - 10.3390/jpm13040668
M3 - Other contribution
SN - 2075-4426
ER -